Acquired by Agilent in 2015 in an all-cash transaction, Seahorse Bioscience develops and manufactures cellular bioenergetics analytical instruments, biomanufacturing and consumable labware products for biological research and drug discovery; measuring cell metabolism. Originally doing business as Thermogeic Imaging, the firm was recognized for developing novel, cellular bioenergetic technologies but may be best known for developing the XF Extracellular Flux Analyzer. XF technology makes cellular bioenergetic studies simple, efficient and user-friendly by combining an electro-optical instrument with ‘smart plastic’ cartridges that enable the real-time measurement of cellular bioenergetics in a non-invasive, multi-well microplate format. The first in vitro metabolic measurement, XF technology non-invasively profiles the metabolic activity of cells in minutes, offering scientists a physiologic cell-based assay for the determination of basal oxygen consumption, glycolysis rates, ATP production, and respiratory capacity in a single experiment to assess mitochondrial dysfunction.
